Gene therapy targeting sodium channels shows promise for chronic pain relief

Chronic pain affects roughly one-third of the U.S. population, with particular impact on cancer patients experiencing chemotherapy-induced neuropathy.

For the roughly one-third of Americans living with chronic pain, relief has long come tethered to risk — the risk of dependence, of diminishing returns, of trading one suffering for another. Researchers at NYU have now proposed a different bargain: a gene therapy that does not silence the body's pain machinery outright, but instead interrupts a precise molecular conversation within nerve cells, quieting pain signals without the collateral damage that has made opioids so costly a solution. The work, still awaiting human trials, carries the particular weight of a discovery that has held across s

Gene therapy targeting sodium channels shows promise for chronic pain relief

Cobertura Relacionada

Recibe The Register en tu bandeja